Live webcast discussion featuring
internationally renowned Acute Myeloid Leukemia (AML) Key Opinion
Leaders
Ongoing progress of pivotal, adaptive Phase 3
clinical trial (the "MIRACLE" trial) designed for possible
accelerated approval of Annamycin in combination with cytarabine
for the treatment of relapsed or refractory AML
HOUSTON, Oct. 7, 2024
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
("Moleculin" or the "Company"), a late stage pharmaceutical company
with a broad portfolio of drug candidates targeting hard-to-treat
tumors and viruses, today announced it will host a Virtual Acute
Myeloid Leukemia KOL event on Monday,
October 14th from 11:00
AM – 1:00 PM ET.
For the event, Walter Klemp,
Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of
Moleculin will be joined by key opinion leaders: Michael Andreef, MD, PhD, Professor of Medicine,
Department of Stem Cell Transplantation, Division of Cancer
Medicine, The University of Texas MD
Anderson Cancer Center; Dr. Giovanni
Martinelli, Associate Professor; Department of Medical and
Surgical Sciences, Bologna University; and Mohamad Cherry, MD, Medical Director of
Hematology at Atlantic Health System.
As part of the event, the members of the Moleculin Management
team and participating KOLs will provide an overview of Annamycin,
discuss the use of anthracyclines, how Annamycin could
significantly change the AML treatment landscape, and the Company's
recently announced global Phase 3 pivotal trial for the treatment
of AML patients who are refractory to or relapsed after induction
therapy (R/R AML) (the "MIRACLE" trial).
Interested participants and investors may access the conference
call by dialing (877) 407-0832 (domestic) or (201) 689-8433
(international) and referencing the Moleculin Biotech Conference
Call. A live video webcast of the event will be available on the
Events page under the Investors section of the Company's website
(moleculin.com). A webcast replay will be available two hours
following the live event and will be accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage
pharmaceutical company advancing a pipeline of therapeutic
candidates addressing hard-to-treat tumors and viruses. The
Company's lead program, Annamycin, is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms and
to eliminate the cardiotoxicity common with currently prescribed
anthracyclines. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin
R/R AML AnnAraC Clinical Evaluation)
Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating
Annamycin in combination with cytarabine, together referred to as
AnnAraC, for the treatment of relapsed or refractory acute myeloid
leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the
Company believes it has substantially de-risked the development
pathway towards a potential approval for Annamycin for the
treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of pathogenic viruses, as well as certain cancer
indications.
For more information about the Company, please visit
www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin has attempted to identify
forward-looking statements by terminology including 'believes,'
'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,'
'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,'
'approximately' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-host-virtual-acute-myeloid-leukemia-kol-event-on-october-14-2024-302268324.html
SOURCE Moleculin Biotech, Inc.